Clinical Trials Logo

Communicable Diseases clinical trials

View clinical trials related to Communicable Diseases.

Filter by:

NCT ID: NCT06417983 Not yet recruiting - Fungal Infection Clinical Trials

Topical Application of Essential Oils to Treat Onchomycosis

NailFungus
Start date: May 30, 2024
Phase:
Study type: Observational

Patients with documented onychomycosis of one or more toe nails will be treated with a daily application of a topical lacquer containing several essential oils.

NCT ID: NCT06416709 Recruiting - Lung Injury Clinical Trials

Stem Cell Treatment for Lung Injury Caused by Major Infectious Diseases

Start date: May 10, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this study is to conduct a prospective, double-blind, randomized placebo-controlled clinical trial to investigate the safety and efficacy of mesenchymal stem cells treatment for Lung injury caused by major infectious diseases.

NCT ID: NCT06415474 Not yet recruiting - Clinical trials for Patients With Abdominal Infection

Evolution of the Lymphocyte Phenotype in Patients With Infection in Intensive Care Unit

REAPHEN
Start date: June 1, 2024
Phase: N/A
Study type: Interventional

Patients admitted for polytrauma, severe neurological injury, post-operative monitoring or sepsis/septic shock present with significant inflammation, leading to immunoparalysis, which is responsible for infection, particularly prolonged infection. A study of their lymphocyte phenotype over time could help explore the phenomenon of immunoparalysis.

NCT ID: NCT06413056 Completed - Neonatal Infection Clinical Trials

Micafungin Versus Amphotercine B in Treatment of Invasive Fungal Infection

Start date: October 20, 2022
Phase: Phase 4
Study type: Interventional

The incidence of fungal infection has increased dramatically over the past few decades.This is due to increase in survival rates of preterm neonates, advances in medical technology and drug therapy, broad spectrum antibiotics and parenteral nutrition . The resistance to antifungal agents has increased. This study will assess the efficacy of micafungin versus amphotericin B in neonates with positive fungal culture.

NCT ID: NCT06412523 Active, not recruiting - Clinical trials for Central Nervous System Infections

Device-related Central Nervous System Infections in Adult Intensive Care Units in Brazil

IMPACTO-SNC
Start date: August 15, 2022
Phase:
Study type: Observational

Resistant microorganisms are public health problems because they affect the treatment of infectious diseases and the survival of patients. Neurosurgical procedures with placement of intracranial pressure monitoring and external ventricular drainage devices are related to increased morbidity and mortality. In Brazil, there are several multicenter studies demonstrating the prevalence and types of resistant microorganisms, however, there is a lack of data related to central nervous system infections associated with invasive devices, which can have a direct impact on prevention and treatment policies.

NCT ID: NCT06410053 Recruiting - Infectious Disease Clinical Trials

The All Ireland Infectious Diseases Cohort Project

AIID
Start date: March 2011
Phase:
Study type: Observational

The All-Ireland Infectious Diseases (AIID) Cohort is a multicentre, prospective, longitudinal observational cohort that enrols consecutive adult subjects attending participating institutions for infectious disease services. This is an ongoing prospective observational cohort of unlimited duration.

NCT ID: NCT06407232 Not yet recruiting - Clinical trials for Cytomegalovirus Infections

Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Start date: June 2024
Phase: Phase 3
Study type: Interventional

This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.

NCT ID: NCT06405958 Not yet recruiting - Clinical trials for Microbial Colonization

Gut Microbiome Analysis in Organ Transplant Recipient

Start date: July 1, 2024
Phase:
Study type: Observational

The microbiome acts as an antigen and can induce signaling through receptors like TLRs and NODs. Microbial metabolites can directly act on gut cells or reach other organs systemically. Studies show that the commensal, non-pathogenic microbiota plays an important role in regulating the immune system in various ways: - Promoting differentiation of Th17 cells and ILC3 signaling to regulate IL-17A production - Influencing iNKT cell generation early in life to prevent inflammatory activities - Facilitating CD4+ T cell differentiation and balancing Th1/Th2 responses - Inducing regulatory T cells (Tregs) that promote immune homeostasis - Tregs in Peyer's patches help maintain a microbiome that supports homeostasis The microbiome influences T cells, B cells and immune homeostasis. This has implications for transplantation, where modulating the microbiome could impact the graft's acceptance by affecting the recipient's immune cells that respond to the transplant. In summary, it highlights the microbiome's role in immune regulation and the potential for leveraging this interaction therapeutically, including in the context of transplantation.

NCT ID: NCT06404307 Not yet recruiting - Clinical trials for Bacterial Infections

Self-administration in Outpatient Parenteral Antimicrobial Therapy Service

SELF-OPAT
Start date: May 2024
Phase: N/A
Study type: Interventional

Home Outpatient Parenteral Antimicrobial Treatment (Home-OPAT) is a service provided to patients that receive antibiotics via infusion but are clinically well enough to go home. A nurse will visit the patient daily to administer the antibiotics. However, the patient or a caregiver can also administer the antibiotics without the help of a nurse. This is called Self-OPAT. The Self-OPAT service is already in practice internationally but not yet in the Netherlands. The goal of this observational study is to assess the possibility to implement Self-OPAT in the Dutch context. The main questions it aims to answer are: Which patients are suitable for Self-OPAT services? How can patients be trained adequately for performing Self-OPAT? What are the experiences of patients with Self-OPAT? How much nurse engagement is needed during Self-OPAT? Is the outcome of treatment with Self-OPAT comparable to Home-OPAT? How do the costs of Self-OPAT differ from the costs of Home-OPAT? How can you implement an Self-OPAT program in the hospital? Participants will be trained by a nurse to administer the infusion antibiotics. They will then administer the antibiotics themselves for as long as the duration of treatment. Every week a nurse will visit to check the progression of the treatment and check the functioning and hygiene of the infusion materials. After a month participants will fill-out a questionnaire about their experience with Self-OPAT.

NCT ID: NCT06402591 Active, not recruiting - Clinical trials for Surgical Site Infection

Results of Extended Versus Single Dose Antibiotic Prophylaxis In Orthopedic Revision Arthroplasty in Nijmegen.

REViSION
Start date: January 1, 2019
Phase: Phase 3
Study type: Interventional

The goal of this randomized control trial is to investigate the superiority of 5 days (extended) versus a single dose of cefazolin prophylaxis in revision arthroplasty of the hip and knee. The main question[s] it aims to answer are: - Is an extended regimen compared to a single dose of cefazolin associated with an increased infection-free implant survival within one year after index revision arthroplasty of the hip or knee? - What are the incidence, risk factors, treatment outcome and prognosis of surgical site infections and periprosthetic joint infection during follow-up? - What is the safety and tolerance of the antimicrobial prophylaxis regimens used? - What are the antimicrobial susceptibility patterns of micro-organisms causing PJI during follow-up? - What is the patient' physical performance and satisfaction of subjects within 1 year after the index revision arthroplasty, using patient related outcome measurements (PROMS)? [question 2] Participants will [describe the main tasks participants will be asked to do, treatments they'll be given and use bullets if it is more than 2 items]. If there is a comparison group: Researchers will compare [insert groups] to see if [insert effects].